Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

The DNA synthesis market is growing as demand for DNA synthesis products and services increases across various applications, with significant growth in North America, Europe, and Asia Pacific.Austin, ...

PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...

To determine the type and severity of a cancer, pathologists typically analyze thin slices of a tumor biopsy under a microscope.

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...